When did Ultragenyx Pharmaceutical report Q4 2024 earnings?

Ultragenyx Pharmaceutical (RARE) reported Q4 2024 earnings on February 13, 2025 after market close.

What were Ultragenyx Pharmaceutical's Q4 2024 revenue and EPS?

Ultragenyx Pharmaceutical reported revenue of $164.9M and eps of $-1.39 for Q4 2024.

Did Ultragenyx Pharmaceutical beat estimates in Q4 2024?

Revenue beat the consensus estimate of $158.7M by $6.2M. EPS missed the consensus estimate of $-1.32 by $0.07.

Where can I find Ultragenyx Pharmaceutical's Q4 2024 SEC filings?

You can read the 10-K periodic report (0000950170-25-023312) directly on SEC EDGAR. The filing index links above go to sec.gov.

Ultragenyx Pharmaceutical RARE Q4 2024 Annual earnings

Reported February 13, 2025 · After market close

Revenue$164.9MBeat by $6.2M

EPS-$1.39Miss by $0.07

Revenue estimate$158.7M

EPS estimate-$1.32

Next report

Aug 4, 2026 (In 4 days)

Revenue estimate$183.1M

EPS estimate-$1.21

Financials

Q4 2024

Income statement

See full

Revenue$164.6M+29.5%

Operating income-$122.3M-0.4%

Net income-$133.2M-7.8%

EPS (diluted)-$1.38+4.2%

Balance sheet

See full

Cash & equivalents$174.0M-18.7%

Total debt$40.3M-6.6%

Total equity$255.0M-7.3%

Total assets$1.5B+0.8%

Cash flow

See full

Operating cash flow-$79.3M+5.7%

CapEx$163.0K-87.8%

Free cash flow-$79.5M+7.0%

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$3.88B+0.2%

Enterprise value$3.75B+1.2%

P/S6.9×-2.0×

Profitability

See full

Operating margin-95.7%-20.3pp

Net margin-101.6%-21.8pp

FCF margin-75.2%-20.4pp

Returns & leverage

See full

Return on equity-214.7%+26.3pp

Debt / equity0.2×0.0×

Current ratio2.4×-0.2×

Segments

By geography

See full

North America$116.5M+25.6%

EMEA$25.6M—

Latin America$18.8M+5.3%

Asia Pacific$3.6M—

By product

See full

Collaboration And Royalty$115.9M+23.2%

Royalty$93.2M+22.5%

Non Cash Royalty$33.6M+23.0%

Versus estimates

Revenue

Q1 2026$136.0MMiss by $22.2M Q4 2025$207.0MBeat by $8.4M Q3 2025$159.9MMiss by $39.8M Q2 2025$166.5MBeat by $547.9K Q1 2025$139.3MMiss by $23.1M

Q4 2024$164.9MBeat by $6.2M

Diluted EPS

Q1 2026-$1.84Miss by $0.35 Q4 2025-$1.29Miss by $0.09 Q3 2025-$1.81Miss by $0.58 Q2 2025-$1.17Beat by $0.10 Q1 2025-$1.57Miss by $0.03

Q4 2024-$1.39Miss by $0.07

Ask the moment Ultragenyx Pharmaceutical reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Ultragenyx Pharmaceutical report Q4 2024 earnings?: Ultragenyx Pharmaceutical (RARE) reported Q4 2024 earnings on February 13, 2025 after market close.
What were Ultragenyx Pharmaceutical's Q4 2024 revenue and EPS?: Ultragenyx Pharmaceutical reported revenue of $164.9M and eps of $-1.39 for Q4 2024.
Did Ultragenyx Pharmaceutical beat estimates in Q4 2024?: Revenue beat the consensus estimate of $158.7M by $6.2M. EPS missed the consensus estimate of $-1.32 by $0.07.
Where can I find Ultragenyx Pharmaceutical's Q4 2024 SEC filings?: You can read the 10-K periodic report (0000950170-25-023312) directly on SEC EDGAR. The filing index links above go to sec.gov.